ProCE Banner Activity

Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types: Answering Clinician Questions

Podcast Episodes
Listen to John L. Marshall, MD; Jamie E. Chaft, MD; and Scot Niglio, MD, answer audience questions from a live CCO Webinar on biomarker testing and the impact on immunotherapy treatment for diverse solid tumors including the latest on PD-L1, dMMR/MSI-high, tumor mutation burden, and other emerging biomarkers.

Released: August 10, 2020

Expiration: August 09, 2021

Share

Faculty

Jamie E. Chaft

Jamie E. Chaft, MD

Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Scot Niglio

Scot Niglio, MD

Medical Oncologist
Bethesda, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Merck Sharp & Dohme Corp.

Program Director Disclosure

Program Director

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees and fees for non-CME/CE services from Amgen, Bayer, Celgene, Genentech, Merck, and Taiho and salary from Caris and Indivumed.

Faculty Disclosure

Primary Author

Jamie E. Chaft, MD

Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Jamie E. Chaft, MD, has disclosed that she has received consulting fees and funds for research support (paid to her institution) from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck.

Scot Niglio, MD

Medical Oncologist
Bethesda, Maryland

Scot Niglio, MD, has disclosed that his spouse/partner has received a salary from Stemcell Technologies.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra D. Cravens, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.